Is amitriptyline a selective serotonin reuptake inhibitor (SSRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, amitriptyline is NOT a selective serotonin reuptake inhibitor (SSRI)

Amitriptyline is a tricyclic antidepressant (TCA), not an SSRI. These are two distinct classes of antidepressants with fundamentally different mechanisms of action 1.

Mechanism of Action

Amitriptyline works by inhibiting the reuptake of both norepinephrine AND serotonin (dual reuptake inhibition), rather than selectively targeting serotonin alone 1, 2. According to the FDA drug label, amitriptyline "inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons" 1. This dual action is what distinguishes TCAs from SSRIs.

Additionally, amitriptyline has multiple other pharmacological effects including:

  • Blockade of muscarinic (anticholinergic) receptors
  • Alpha-1 adrenergic receptor blockade
  • Histamine H1 receptor blockade 3

These additional receptor effects explain common side effects like dry mouth, sedation, and constipation that are characteristic of TCAs but not SSRIs.

Key Distinctions from SSRIs

SSRIs selectively inhibit only serotonin reuptake at presynaptic nerve endings 3. Examples include fluoxetine, sertraline, paroxetine, citalopram, and escitalopram. The guidelines explicitly distinguish between these two drug classes when making treatment recommendations 3, 4.

Research demonstrates that amitriptyline, as a tertiary amine TCA with dual reuptake inhibition, may actually be more effective than SSRIs for severe depression, particularly in hospitalized patients 5, 6, 7. This superior efficacy is attributed to its dual action on both serotonin and norepinephrine, rather than the selective serotonin action of SSRIs 5.

Clinical Implications

The distinction matters clinically because:

  • TCAs like amitriptyline have more anticholinergic side effects and are less well tolerated than SSRIs 6, 7
  • Drug interactions differ significantly - while SSRIs inhibit cytochrome P450 2D6, TCAs are substrates of this enzyme 1
  • Toxicity in overdose is much higher with TCAs compared to SSRIs 8

The classification of amitriptyline as a TCA rather than an SSRI is consistently maintained across all major clinical guidelines 3, 9, 3, 10, 4, 11, 8.

References

Research

Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials.

The British journal of psychiatry : the journal of mental science, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.